SYLVANT
Biological
RECORDATI_RARE_DISEASES_INC.
Total Payments
$507,112
Transactions
1,847
Doctors
1,339
Companies
5
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $453,969 | 1,165 | 877 |
| 2023 | $14,032 | 660 | 588 |
| 2020 | $13,400 | 10 | 10 |
| 2019 | $50.32 | 3 | 3 |
| 2017 | $25,660 | 9 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $302,110 | 18 | 59.6% |
| Honoraria | $94,607 | 40 | 18.7% |
| Consulting Fee | $56,728 | 23 | 11.2% |
| Food and Beverage | $42,985 | 1,735 | 8.5% |
| Travel and Lodging | $5,706 | 18 | 1.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $4,975 | 13 | 1.0% |
Payments by Type
Research
$302,110
18 transactions
General
$205,002
1,829 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| YUANQUAN Yang at Ohio State on A Phase 2 Study: Checkpoint Inhibitor Rechallenge in combination with Siltuximab for pts who had prior irAE | RECORDATI_RARE_DISEASES_INC. | $106,145 | 1 |
| Cytokine Release Syndrome in CAR-T Treatment | RECORDATI_RARE_DISEASES_INC. | $37,500 | 0 |
| Mayur Narkhede at University of Alabama at Birmingham on Cytokine Release Syndrome in CAR-T Treatment | RECORDATI_RARE_DISEASES_INC. | $37,500 | 1 |
| Mayur Narkhede at University of Alabama at Birmingham on Pharmacokinetic profile of siltuximab during ongoing CRS/ICANS in patients receiving CAR T-cell therapy | RECORDATI_RARE_DISEASES_INC. | $30,000 | 1 |
| Pharmacokinetic profile of siltuximab during ongoing CRS/ICANS in patients receiving CAR T-cell therapy | RECORDATI_RARE_DISEASES_INC. | $30,000 | 0 |
| Timothy Voorhees at Ohio State on Prevention of Cytokine Release Syndrome in CAR-T Treatment | RECORDATI_RARE_DISEASES_INC. | $17,375 | 1 |
| Caimi Paolo at Cleveland Clinic on Pilot study of siltuximab CRS prophylaxis prior to treatment with epcoritamab, a CD3/CD20 bispecific antibody for treatment of B cell lymphomas | RECORDATI_RARE_DISEASES_INC. | $8,965 | 1 |
| Pilot study of siltuximab CRS prophylaxis prior to treatment with epcoritamab, a CD3/CD20 bispecific antibody for treatment of B cell lymphomas | RECORDATI_RARE_DISEASES_INC. | $8,965 | 0 |
Top Doctors Receiving Payments for SYLVANT
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , M.D | Medical Oncology | Columbus, OH | $106,145 | 1 |
| Unknown | — | Portland, OR | $102,885 | 16 |
| , M.D | Hematology & Oncology | Birmingham, AL | $72,645 | 7 |
| , MD | Hematology & Oncology | Lansing, MI | $31,205 | 20 |
| , M.D | Medical Oncology | Columbus, OH | $17,375 | 2 |
| , MD | Nephrology | Salt Lake City, UT | $15,660 | 4 |
| , MD | Hematology | Dallas, TX | $12,668 | 9 |
| , MD, PHD | Molecular Genetic Pathology | Durham, NC | $11,983 | 8 |
| , MD | Internal Medicine | Royal Oak, MI | $10,629 | 6 |
| , M.D | Internal Medicine | Cleveland, OH | $8,965 | 1 |
| Gaurav Goyal | Hematology & Oncology | Birmingham, AL | $7,909 | 3 |
| , M.D., PH.D | Hematology | Los Angeles, CA | $7,752 | 6 |
| , M.D | Hematology & Oncology | Milwaukee, WI | $7,530 | 4 |
| , MD | Hematology & Oncology | Little Rock, AR | $7,140 | 1 |
| , M.D., PH.D | Hematology | Stanford, CA | $6,772 | 8 |
| , M.D | Hematology | Atlanta, GA | $5,080 | 2 |
| , MD | Hematology & Oncology | Miami, FL | $4,410 | 1 |
| , M.D., PHD | Hematology & Oncology | Philadelphia, PA | $4,080 | 1 |
| , D.O | Internal Medicine | Omaha, NE | $3,740 | 3 |
| , MD, PHD, MPH | Internal Medicine | Rochester, MN | $3,080 | 2 |
| , MD | Pediatric Hematology-Oncology | Atlanta, GA | $3,000 | 1 |
| , M.D | Hematology | San Francisco, CA | $3,000 | 1 |
| , MD | Infectious Disease | Seattle, WA | $3,000 | 1 |
| Anuj Mahindra | — | La Jolla, CA | $1,000 | 1 |
| , M.D | Internal Medicine | Las Vegas, NV | $1,000 | 1 |
Ad
Manufacturing Companies
- RECORDATI_RARE_DISEASES_INC. $468,001
- Janssen Research & Development, LLC $25,660
- EUSA Pharma (US) LLC $13,400
- Janssen Biotech, Inc. $32.68
- Janssen Scientific Affairs, LLC $17.64
Product Information
- Type Biological
- Total Payments $507,112
- Total Doctors 1,339
- Transactions 1,847
About SYLVANT
SYLVANT is a biological associated with $507,112 in payments to 1,339 healthcare providers, recorded across 1,847 transactions in the CMS Open Payments database. The primary manufacturer is RECORDATI_RARE_DISEASES_INC..
Payment data is available from 2017 to 2024. In 2024, $453,969 was paid across 1,165 transactions to 877 doctors.
The most common payment nature for SYLVANT is "Unspecified" ($302,110, 59.6% of total).
SYLVANT is associated with 8 research studies, including "YUANQUAN Yang at Ohio State on A Phase 2 Study: Checkpoint Inhibitor Rechallenge in combination with Siltuximab for pts who had prior irAE" ($106,145).